Can Fite Biopharma Aktie [WKN DE: A1W6SX / ISIN: US13471N1028]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

30.12.22		Can-Fite Announces ADS Ratio Change (Businesswire)
28.12.22		Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer (Businesswire)
25.11.22		Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update (Businesswire)
02.11.22		Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston (Businesswire)
25.10.22		Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting® (Businesswire)
13.10.22		Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference (Businesswire)
12.09.22		Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology (Businesswire)
25.08.22		Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update (Businesswire)
23.08.22		Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania (Businesswire)
22.08.22		Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress (Businesswire)
17.08.22		Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix (Businesswire)
11.07.22		Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis (Businesswire)
29.06.22		Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis (Businesswire)
24.06.22		Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia (Businesswire)
09.06.22		Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal (Businesswire)
26.05.22		Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update (Businesswire)
16.05.22		Can-Fite Granted Key NASH Patent in Israel (Businesswire)
02.05.22		Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit (Businesswire)
05.04.22		Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug (Businesswire)
28.03.22		Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022 (Businesswire)
24.03.22		Can-Fite Reports 2021 Financial Results & Provides Clinical Update (Businesswire)
14.03.22		Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office (Businesswire)
11.03.22		Can-Fite’s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv (Businesswire)
08.03.22		Can-Fite’s Phase III Psoriasis Study Data Expected Q2 2022 (Businesswire)
08.07.21		Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study (Businesswire)
28.06.21		Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets (Businesswire)
16.06.21		Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment (Businesswire)
02.06.21		Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson (Businesswire)
02.06.21		Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021 (Businesswire)
27.05.21		Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update (Businesswire)
27.05.21		Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® (Businesswire)
06.05.21		Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021 (Businesswire)
29.04.21		Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 (Businesswire)
22.04.21		Can-Fite Expands its Phase II COVID-19 Study to Europe (Businesswire)
20.04.21		Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates (Businesswire)
05.04.21		Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies (Businesswire)
30.03.21		Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million (Businesswire)
25.03.21		Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update (Businesswire)
19.03.21		Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® (Businesswire)
18.03.21		Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model (Businesswire)
16.03.21		Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma (Businesswire)
05.03.21		Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol (Businesswire)
22.02.21		New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson (Businesswire)
01.02.21		Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies (Businesswire)
28.01.21		Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH” (Businesswire)
08.01.21		Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers (Businesswire)
15.12.20		Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs (Businesswire)
14.12.20		Can-Fite Reports on Progress With Its Namodenoson NASH Program (Businesswire)
03.12.20		Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 (Businesswire)
30.11.20		Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Elon Musk prognostiziert Kursrückgang bei Bitcoin

Solana Kurs Prognose: 1.000 US-Dollar in 2025?

DeepSeek sorgt nur noch partiell für anhaltenden Schock: SoftBank-Aktien & Co. auf Talfahrt - NVIDIA nach Rekordverlust erholt

NVIDIAs Joint Venture "Stargate" als wegweisender Schritt für KI-Investitionen?

Marktunruhe belastet Bitcoin-Kurs

Novartis-Aktie zieht an: Novartis erhöht Dividende nach beeindruckendem Umsatz- und Gewinnplus

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	02.02.2025 04:52
Kaufwert:	EUR
	Hinzufügen Speichern